naa a22 4500 510764460 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s12094-012-0902-3 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0902-3 Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function [Elektronische Daten] [Jon Zugazagoitia, Aránzazu Manzano, Javier Sastre, Jose Ladero, Javier Puente, Eduardo Díaz-Rubio] Objective: Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma, regardless of the liver functional reserve. We present a single institutional series of Child-Pugh A and Child-Pugh B patients treated with sorafenib with the aim to establish the efficacy and safety of sorafenib in patients of daily clinical conditions and to compare these results between Child-Pugh A and Child-Pugh B patients. Materials and methods: A total of 51 patients were treated with sorafenib 400mg/12h until disease progression or unacceptable toxicity. Results: The median progression-free survival and overall survival for the overall population were 3.5 and 8.2months, respectively, with a 1-year survival rate of 27%. Overall survival was significantly longer for patients Child-Pugh A compared with those with Child-Pugh B liver function (8.7 vs. 4.7months, respectively). The most common adverse events were fatigue (62.7%), diarrhea (58%), hypertension (31.3%), and hand-foot syndrome (31.3%), and in most cases grade 1 or 2 according to the NCI-CTC 3.0. Grade 4 liver-related events occurred mainly in Child-Pugh B patients with decompensated cirrhosis at the time of sorafenib initiation (54.5% of that group). Discussion: The benefit of sorafenib in Child-Pugh B patients, if exist, may be limited by frequent liver-related events, especially in decompensated patients, and then, toxicity and impact in quality of life should be carefully monitored. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Child-Pugh score nationallicence Hepatocellular carcinoma nationallicence Sorafenib nationallicence Liver-related events nationallicence Compensated cirrhosis nationallicence Decompensated cirrhosis nationallicence Zugazagoitia Jon Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut Manzano Aránzazu Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut Sastre Javier Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut Ladero Jose Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain aut Puente Javier Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut Díaz-Rubio Eduardo Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 146-153 1699-048X 15:2<146 2013 15 12094 https://doi.org/10.1007/s12094-012-0902-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0902-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zugazagoitia Jon Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut NATIONALLICENCE 700 1- Manzano Aránzazu Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut NATIONALLICENCE 700 1- Sastre Javier Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut NATIONALLICENCE 700 1- Ladero Jose Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain aut NATIONALLICENCE 700 1- Puente Javier Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut NATIONALLICENCE 700 1- Díaz-Rubio Eduardo Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), c/Martin Lagos s/n, 28040, Madrid, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 146-153 1699-048X 15:2<146 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer